Corrigendum: Longitudinal "Real-World" outcomes of pirfenidone in idiopathic pulmonary fibrosis in Greece [Front Med, 4, 213, (2017)] doi: 10.3389/fmed.2017.00213

In the original article, there was a mistake in Figure 1 as published [x and y axes were mislabeled and *p-value < 0.05 indicating significance was missing]. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. © 2018 Tzouvelekis, Karampitsakos, Ntolios, Tzilas, Bouros, Markozannes, Malliou, Anagnostopoulos, Granitsas, Steiropoulos, Dimakou, Chrysikos, Koulouris and Bouros

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece

Background: Nintedanib represents an antifibrotic compound able to slow down disease progression of patients with idiopathic pulmonary fibrosis (IPF). Objective: To investigate the safety and efficacy of nintedanib in patients with IPF in a real-life setting. Methods: This was a multicentre, retrospective, observational, real-life study for patients with IPF receiving nintedanib between October 2014 and October 2016. Results: We identified 94 patients with IPF receiving nintedanib (72 males, mean age±SD: 73.8 ± 7.5, mean%FVC±SD = 68.1 ± 18.3, mean%DLCo±SD = 44.4 ± 14.5). Diarrhea (n = 52, 55.3%) was the most commonly reported adverse event. Twenty patients (21.2%) had to permanently discontinue nintedanib due to severe adverse events. In the 6-months follow-up, median decline in %FVC predicted and %DLCO predicted were 1.36 (95%Cl: 0 to 2.97) and 4.00 (95%Cl: 2.01 to 6.20), respectively, when deaths were censored and excluded from the analysis. At 12 months, mean%FVC±SD and mean%DLCo±SD were 64.5 ± 19.1 and 43.7 ± 15.4, respectively. With regards to mortality, 17 patients (18.1%) died over a study period of 730 days. Conclusion: Nintedanib demonstrated an acceptable safety and efficacy profile in our real-world observational study. Prospective observational studies in the context of registries that collect well-defined supporting data over time are sorely needed to answer residual questions on drug's performance. © 2018 Elsevier Lt